Home > NEWS
The top 10 drug launches of 2019
release time:2019-06-26

Cancer is probably the most sought-after indication in the biopharma world, but it’s missing from 2019's class of top drug launches. Instead, treatments in immunology and rare genetic diseases have grabbed the limelight.

We considered two EvaluatePharma projections in January and February to rank this year’s top 10 drug launches by 2024 sales. At the top of the list is Alexion’s Soliris follow-up, Ultomiris, which nabbed an FDA nod at the end of 2018, two months ahead of its scheduled decision date.

As part of CEO Ludwig Hantson’s plan for Alexion to pivot away from ultrarare diseases and reach more patients, the biotech has priced Ultomiris at a 10% discount to Soliris and is aiming to convert 70% of Soliris patients to the improved therapy. Paroxysmal nocturnal hemoglobinuria (PNH), the current condition Ultomiris is approved in, is a rare disease that involves the immune system.

Notably, two gene therapies are included here: Novartis’ spinal muscular atrophy treatment Zolgensma—which could challenge Biogen’s SMA treatment Spinraza—and Bluebird Bio’s Zynteglo for beta-thalassemia. Gene therapies have attracted much interest and controversy alike. As one-time treatments, they come with big efficacy promises, but pricing of these two drugs has been closely watched, and both companies are offering up novel models such as installments paid over several years.

Novartis boasts three drugs on our list, the most among all companies, putting CEO Vas Narasimhan’s innovative medicine-focused strategy to an early test. Besides Zolgensma, the Swiss drugmaker has brolucizumab, a wet age-related macular degeneration therapy that will go up against Bayer and Regeneron’s Eylea and its Roche-partnered Lucentis. In head-to-head studies, brolucizumab topped Eylea in some secondary endpoints.

Copyright Copyright (C) 2015-2035 Senova Technology Co. Ltd.
Address: 311# in Building 3 of North Area, Dayuan Industry Park, Xili, Nanshan District of Shenzhen,China 518055  Tel: +86-0755-8670 3119 QQ: 530953397